Publish in this journal
Journal Information
Vol. 67. Issue 6.
Pages 499-500 (June 2014)
Vol. 67. Issue 6.
Pages 499-500 (June 2014)
Letter to the Editor
Full text access
New Data About Atrial Fibrillation, Comment to the OFRECE Study. Response
Nuevos datos sobre fibrilación auricular, observaciones al estudio OFRECE. Respuesta
Visits
5995
Juan José Gómez-Doblasa,
Corresponding author
jjgomezdoblas@secardiologia.es

Corresponding author:.
, Javier Muñizb, Joaquín J. Alonso Martínc, Eulalia Roigd
a Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
b Instituto Universitario de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain
c Servicio de Cardiología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
d Servicio de Cardiología, Hospital de Sant Pau, Barcelona, Spain
Related content
Rev Esp Cardiol. 2014;67:49910.1016/j.rec.2014.01.004
Rafael Vidal-Pérez, Fernando Otero-Raviña, Manuel Otero-Mata, José Ramón González-Juanatey
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
To the Editor,

We appreciate the interest shown by Vidal-Pérez et al. in our article published recently in Revista Española de Cardiología,1 which provides us with an opportunity to present some interesting additional information not included in the article itself. We agree on the importance of knowing the thromboembolic risk of the population included in the OFRECE study, both for patients with a diagnosis of atrial fibrillation and for the general population. In our study, the mean (standard deviation) CHADS2 and CHAD2DS2-VASc of patients with atrial fibrillation was 2.3 (1.3) and 3.8 (1.6), respectively. In the general population, the mean (standard deviation) CHADS2 and CHAD2DS2-VASc of patients with atrial fibrillation was 0.8 (1) and 1.8 (1.5), respectively. The distribution of both scales is in agreement with that of the Val-FAAP and AFABE studies,2,3 although the similarity is greater in the 2 population-based studies (Figure). These data are, we believe, relevant because they show that the level of risk in the population with atrial fibrillation is very similar to that of the populations included in clinical trials with new oral anticoagulants. In addition, an increasing body of evidence suggests that thromboembolic risk, as measured with these scales in the population without a diagnosis of atrial fibrillation, is associated with the onset of events.4

Figure.

Prevalences by thromboembolic risk scales in the OFRECE, AFABE, and Val-FAAP studies.

(0.12MB).

References
[1]
J.J. Gómez-Doblas, J. Muñiz, J.J. Alonso Martin, G. Rodríguez-Roca, J.M. Lobos, P. Awamleh, et al.
Prevalencia de fibrilación auricular en España Resultados del estudio OFRECE.
Rev Esp Cardiol, 67 (2014), pp. 259-269
[2]
V. Barrios, A. Calderón, C. Escobar, M. de la Figuera.
Pacientes con fibrilación auricular asistidos en consultas de atención primaria Estudio Val-FAAP.
Rev Esp Cardiol, 65 (2012), pp. 47-53
[3]
J.L. Clua-Espuny, I. Lechuga-Duran, R. Bosch-Princep, A. Roso-Llorach, A. Panisello-Tafalla, J. Lucas-Noll, et al.
Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes.
Estudio AFABE. Rev Esp Cardiol, 66 (2013), pp. 545-555
[4]
G. Ntaios, G.Y. Lip, K. Makaritsis, V. Papavasileiou, A. Vemmou, E. Koroboki, et al.
CHADS2.
CHA2S2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology, 80 (2013), pp. 1009-1017
Copyright © 2014. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?